Novo Nordisk and Ebn Sina Medical Host Second ACT Summit in Qatar

Following the “remarkable” success of the inaugural ACT Summit held in Dubai in May, Novo Nordisk Qatar, under Ebn Sina Medical Company hosted the second edition of ACT Summit (Advancing Cardio-Metabolic Treatment) in Doha on October 17 and 18.

Ebn Sina is a subsidiary of Aamal Company.

The two-day scientific summit gathered over 350 healthcare professionals specialised in obesity and diabetes management from more than 12 countries, including Qatar, other GCC countries, Pakistan, Iraq, and Kazakhstan.

The event focused on addressing the pressing issues surrounding cardiovascular kidney metabolic complications of Type 2 diabetes and obesity, emphasising the importance of a multidisciplinary approach to enhance patient outcomes and improve long-term weight loss; glycaemic control and the complications of obesity and diabetes; and exploring the role that the semaglutide therapies may play in combating these diseases.

Renowned healthcare Professionals from Qatar and worldwide including Germany; USA; Canada and Italy shared cutting-edge insights into emerging treatment strategies and the importance of continuity of care in obesity starting from adolescence to adulthood, clinical innovations, and new models of integrated care.

Manvendra Singh, General Manager, Novo Nordisk Qatar, stated:

“ACT Summit reinforces Novo Nordisk’s commitment to advancing cardio-metabolic education and empowering healthcare professionals with the latest scientific insights. Hosting this event in Doha reflects Qatar’s growing role as a regional hub for medical excellence and collaboration.

“As Qatar and the region continue to face high rates of obesity, diabetes, and cardiovascular disease, ACT Summit is vital. Together, we are committed to strengthening the healthcare landscape and improving patient outcomes through innovative, science-driven solutions.

Rashid al-Mansoori, CEO, Aamal Company added: “I am pleased to take part in this important summit and address a distinguished audience from the medical sector. We are proud that Aamal’s subsidiary Ebn Sina Medical, continues to partner with leading global innovators like Novo Nordisk.

“The ACT Summit 2 demon-strates our shared dedication to elevating medical education and supporting Qatar’s vision of improving public health outcomes.”

Throughout the two-day event, participants engaged in plenary discussions, case-based learning, and interactive workshops exploring the interconnection between obesity, diabetes, and cardio-renal complications.

The summit concluded with a shared call to action — to advance integrated care and accelerate collaborative solutions to reduce the regional burden of cardio-metabolic diseases.